Pfizer in technology licensing deal with Xoma

Share this article:

Drug developer Xoma announced that it has licensed technology to Pfizer that can be used to screen and make antibody products, the Associated Press reported.

Xoma said it will license the technology for an upfront payment of $30 million, along with future royalty and milestone payments.

Xoma also licenses the technology to companies including Merck, Centocor and Alexion Pharmaceuticals. Xoma receives royalties from Genentech for its macular degeneration drug Lucentis because that drug uses its bacterial cell expression technology.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.